Coherus Oncology Dismisses Ernst & Young, Appoints PwC as Independent Auditor

On June 12, 2026, Coherus Oncology, Inc. dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm. The decision was made by the Audit Committee of the Board of Directors. EY's reports on the company's financial statements for the fiscal years ended December 31, 2025, and 2024, contained no adverse opinions or qualifications. During those years and the subsequent interim period, there were no disagreements with EY on accounting principles or practices. The company noted a previously reported material weakness regarding inventory account reconciliations in 2024, which was remediated by the end of 2025. Concurrently, the Audit Committee selected PricewaterhouseCoopers LLP (PwC) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. Coherus confirmed it had not consulted with PwC on any accounting matters prior to their appointment. EY provided a letter to the SEC agreeing with these statements.